RESEARCH ARTICLE

Polymorphism of the DNA Repair Gene XRCC1 (Arg194Trp) and its role in Colorectal Cancer in Kashmiri Population: a Case Control Study

Saniya Nissar1,2,3, Aga Syed Sameer4, Roohi Rasool2, Nissar A Chowdri5, Fouzia Rashid3*

Abstract

**Background:** Genetic polymorphisms in DNA repair genes may influence individual variation in DNA repair capacity, which may be associated with risk of developing cancer. For colorectal cancer the importance of mutations in mismatch repair genes has been extensively documented. **Materials and Methods:** In this study we focused on the Arg194Trp polymorphism of the DNA repair gene XRCC1, involved in base excision repair (BER) and its role in colorectal cancer in Kashmiri population. A case-control study was conducted including 100 cases of colorectal cancer, and 100 hospital-based age- and sex-matched healthy controls to examine the role of XRCC1 genetic polymorphisms in the context of colorectal cancer risk for the Kashmiri population. **Results:** Genotype analysis of XRCC1 Arg194Trp was conducted with a restriction fragment length polymorphism (RFLP) method. The overall association between the XRCC1 polymorphism and the CRC cases was found to be significant ($p < 0.05$) with both the heterozygous genotype (Arg/Trp) as well as homozygous variant genotype (Trp/Trp) being moderately associated with the elevated risk for CRC [OR=2.01 (95% CI=1.03-3.94) and OR=5.2 (95% CI=1.42-19.5)] respectively. **Conclusions:** Our results suggest an increased risk for CRC in individuals with XRCC1 Arg194Trp polymorphism suggesting BER repair pathway modulates the risk of developing colorectal cancer in the Kashmiri population.

Keywords: Colorectal cancer - Kashmir - polymorphism - DNA repair - RFLP - XRCC1 - BER

Asian Pac J Cancer Prev, 16 (15), 6385-6390

Introduction

Colorectal cancer (CRC) is the third most common cancer worldwide and the second leading cause of cancer-related death in many parts of the Western world (Gellad and Provenzale, 2010). CRC is a commonly diagnosed cancer in both men and women, and ranks third most common cancer in men and second most in women worldwide (Jemal et al., 2011). The incidence of this malignancy shows considerable variation among racially or ethnically defined populations in multiracial/ethnic countries. Kashmir has been reported as a high-incidence area of gastrointestinal cancers (GIT) (Mir et al., 2005; Jemal et al., 2011; Rasool et al., 2012; Sameer, 2013a). In Kashmir valley CRC represents the third most common GIT cancer (Sameer et al., 2012; Sameer, 2013a; 2013b) after esophageal and gastric cancer; and among males CRC ranks as fourth common cancer and third among females (Rasool et al., 2012; Sameer, 2013).

Genetic polymorphisms in DNA repair genes which lead to amino acid substitution may lead to differential capacity to repair DNA damage. This effect has been found to be associated with increased genetic instability and carcinogenesis (de Boer, 2002). In mammalian cells four different DNA repair mechanisms have been identified: base excision repair (BER), nucleotide excision repair (NER), double-strand break repair and mismatch repair (Yu et al., 1999, Christmann et al., 2003). All these DNA repair pathways are finely regulated for the maintenance of genomic integrity and modulation of repair capacity in response to DNA damage and thus susceptibility to CRC (Naccarti et al., 2007).

The BER pathway has a primary role in the repair of oxidative base lesions such as 8-hydroxyguanine, formamidopyrimidines, and 5-hydroxyuracil (Mynard et al., 2009) produced by methylation, oxidation or reduction by ionizing radiation or oxidative damage (Duarte et al., 2005). All these DNA repair pathways are finely regulated for the maintenance of genomic integrity and modulation of repair capacity in response to DNA damage and thus susceptibility to CRC (Naccarti et al., 2007).

1Department of Biochemistry, 2Department of Clinical Biochemistry, University of Kashmir, Hazratbal, 3Department of Immunology and Molecular Medicine, 4Department of Surgery, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, Kashmir, India, 5Department of Basic Medical Sciences, College of Medicine, King Saud Bin Abdul Aziz University for Health Sciences, Jeddah, Kingdom of Saudi Arabia *For correspondence: rashid.fouzia@gmail.com
oxygen species, and methylating and deaminating agents (Lindahl and Wood, 1999; Hoeijmakers, 2001; Wood et al., 2001; Friedberg, 2003).

XRCC1 (X-ray repair cross-complementing group1) gene is located on chromosome 19q13.2-13.3 which codes for a 633 amino acid residue Xrc1 protein (Nissar et al., 2013). Xrc1 protein functions as scaffolding protein with many DNA interacting proteins important of which are DNA polymerase beta, apurinic/apyrimidinic endonuclease 1 (APE1), human 8-oxoguanine glycosylase 1 (hOGG1), poly-(ADP-ribose) polymerase (PARP) and DNA ligase III to facilitate BER and single-strand break-repair (SSBR) processes (Thompson and West, 2000; Vidal et al., 2001; Marsin et al., 2003; Brem and Hall, 2005).

About sixty validated single nucleotide polymorphisms (SNPs) in the XRCC1 gene have been identified till date among which three affect the coding region of the gene namely codons 194 (Arg>Trp), 280 (Arg>His) and 399 (Arg>Gln) (Shen et al., 1998; Skjelbred et al., 2006). These non-conservative amino acid changes may alter Xrc1 function and may have an impact on individual susceptibility to the development of cancers (Marsin et al., 2003; Liu et al., 2013). XRCC1 gene polymorphisms have been reported to be associated with the risk of different kinds of cancers, including bladder cancer, thyroid cancer, lung cancer, breast cancer, gastric cancer, non-melanoma skin cancer, oral cancer as well as colorectal cancer (Abdel-Rahman et al., 2000; Duell et al., 2001; Lee et al., 2002; Mort et al., 2003; Yeh et al., 2005; Wang et al., 2010; Custodio et al., 2011; Chiyomaru et al., 2012; Chen et al., 2012; Du et al., 2013; Nissar et al., 2013; Zhang et al., 2013; Feng et al., 2014).

In the present paper, we conducted a case-control study to examine the role of genetic polymorphism Arg194Trp of DNA repair gene XRCC1 in context of colorectal cancer risk for the Kashmiri Population. Further we also investigated whether there is a link between the clinic-pathological variables with the XRCC1 Arg194Trp genotype and hence its role in modulating the risk of colorectal cancer.

Materials and Methods

Subjects

This study included 100 consecutive primary colorectal cancer patients. All CRC patients were recruited from Department of Surgery, Sher-I-Kashmir Institute of Medical Science. Tumor types and stages were determined by two experienced pathologists. The cases who had not received any chemo or radiotherapy were chosen for this study. Blood samples of 100 age and sex matched individuals with no signs of any malignancy were collected for controls. The mean age of both patient and control groups was 55 years.

Data on all CRC patients were obtained from personal interviews with patients and or guardians (for those who were illiterate), medical records and pathology reports. The data collected included sex, age, dwelling, tumor location, Dukes Stage, lymph node status. All patients and or guardians were informed about the study and their will to participate in this study was taken on predesigned questionnaire (Available on request). The collection and use of tumor and blood samples for this study were previously approved by the appropriate Institutional Ethics Committee.

DNA extraction & genotype analysis:

DNA extraction was performed using Ammonium Acetate Method. One μL of DNA was used as the template for each PCR cycle. Genotype analysis of XRCC1 gene was carried out by PCR-RFLP using primers (F: 5’-GTG AAG GAG GAG GAT GAG AGC-3’; R: 5’-CCC CAG CCC CCT CTA CCC T-3’) generating a fragment of 160 bp as previously described (Figure1) (Custodio et al., 2011). Briefly PCR was carried out in a final volume of 25 μL containing 50 ng genomic DNA template, 1X PCR buffer with 2 mM MgCl₂, 0.5 μM of each primer, 50 μM dNTPs and 0.5 U DNA polymerase. For PCR amplification, the standard program was used as follows: one initial denaturation step at 94°C for 7 min, followed by 35 denaturation cycles of 1 min at 94°C, 1 min of annealing at 60°C, and 1 min of extension at 72°C, followed by a final elongation cycle at 72°C for 10 min.

PCR product of 160 bp was digested by 10 U MspI at 37°C. For codon 194, two bands of 110 and 60 bp were identified as homozygous wild type Arg/Arg, while three bands of 160, 110 and 60 bp was identified as heterozygous variant allele Arg/Trp and the homozygous mutant type

Figure 1. Representative gel picture showing XRCC1 exon 6 Amplicon. Lane M Contains 100 bp DNA Molecular Weight Marker. Lane 1-6 Represent 160 bp Amplicon of Exon6

Figure 2. Representative gel Picture picture showing RFLP analysis of XRCC1 Codon194 against 100 bp Marker. Lane no. 6, 9, 10 and 11 Shows Arg/Arg Wild Genotype; Lane no. 4, 12 and 13 Denotes Trp/Trp Homozygous Mutants and Lane no. 1, 2, 3, 5, 7 and 8 Represent Arg/Trp Heterozygous Variant Respectively
Statistical analysis

The observed frequencies of the above genotypes in patients with CRC were compared with the controls using chi-square or fisher exact tests when the expected frequencies were small. The chi-square test was used to verify whether the genotype distributions were in Hardy-Weinberg equilibrium (for allele and genotype frequencies in our population). Statistical significance was set at p<0.05. Statistical analyses were performed using PASW version 18 software.

Results

A total of 100 cases and 100 control subjects were included in this study with prior consent. All of cases presented constipation and bleeding per rectum as their chief complaint. Furthermore, out of 100 confirmed cases of CRC, 55 males and 45 cases were females (M/F ratio=1.22), 61 were rural and 39 were urban, 44 cases had carcinoma in colon and 56 in rectum and 60 were smokers and 40 non-smokers (Table 1). The mean age of patients having confirmed CRC was 55 years. Among control subjects, 54 consisted of males and 46 females (M/F ratio = 1.17). No significant gender- or age-related differences were observed between the groups (p > 0.05).

Among the CRC cases, we found the frequency of the XRCC1 genotype to be 59.0 per cent (59/100) for Arg/Arg, 29.0 per cent (29/100) for Arg/Trp and 12.0 per cent (12/100) for Trp/Trp, while the frequency in the general control population was 78.0 per cent (78/100) for Arg/Arg, 19.0 per cent (19/100) for Arg/Trp and 3.0 per cent (3/100) for Trp/Trp. The overall association between the XRCC1 polymorphism and the CRC cases was found to be significant (p<0.05) (Table 2). Overall both the heterozygous genotype (Arg/Trp) as well as homozygous variant genotype (Trp/Trp) were associated with the elevated risk for CRC (OR=2.01 (95%CI=1.03-3.94) and OR=5.2 (95%CI=1.42-19.5)). Also, independent analysis for the Arg/Trp and Trp/Trp genotypes revealed a significant association with the risk of CRC (p<0.05). The overall hazard ratio of the XRCC1 Trp allele in CRC was 5.2 (95%CI=1.42-19.5).

The correlation of XRCC1 polymorphic status with the clinico-pathological characteristics was also carefully analyzed. However, we did not find any significant association (p value > 0.05) with any of the characteristic (Table 3).

Discussion

There is increasing evidence that genetic variation leads to different DNA repair capacities in the human population, hence such common polymorphisms can play a role in an individual’s genetic susceptibility to cancer (Berwick and Vineis, 2000). Mutations in XRCC1 gene may lead to decrease or loss of its DNA repair capacity and confer the variation in susceptibility to diverse malignant tumors among individuals. More than 300 SNPs in XRCC1 gene have been demonstrated in previous studies, among which the XRCC1 Arg194Trp and XRCC1

| Table 1. Frequency Distribution Analysis of selected Demographic and Risk Factors in Colorectal Cancer Cases and Control |
| --- |
| Variable | Cases n = 100 | Controls n = 100 | P-Value |
| Age > 50 | 54 | 52 | 0.88 |
| ≤ 50 | 46 | 48 | |
| Sex | | | |
| Males | 55 | 54 | 1 |
| Females | 45 | 46 | |
| Smoking Status | | | |
| Ever | 60 | 55 | 0.56 |
| Never | 40 | 45 | |
| Dwelling | | | |
| Rural | 61 | 58 | 0.77 |
| Urban | 39 | 42 | |

| Table 2. Genotype Frequencies of XRCC1 Gene Polymorphism in CRC Cases & Controls |
| --- |
| XRCC1 Genotype | CRC Cases (n=100) | Controls (n=100) | OR (95% CI); χ²; P-value |
| Arg/Arg – (Wild) | 59 (59.0%) | 78 (78.0%) | 1 |
| Arg/Trp – (Heterozygous) | 29 (29.0%) | 19 (19.0%) | 2.01 (1.03-3.94); 0.03; 0.04 |
| Trp/Trp – (Variant) | 12 (12.0%) | 03 (3.0%) | 5.2 (1.42-19.5); 0.006; 0.01 |

| Table 3. Association between XRCC1 Gene Polymorphism and Clinico-pathologic Characteristics |
| --- |
| Variables | n = 100 | Arg/Arg | Arg/Trp | Trp/Trp | χ², P-value |
| Age group | | | | | |
| > 50 | 54 (54.0%) | 33 | 15 | 6 | 0.23, 0.89 |
| ≤ 50 | 46 (46.0%) | 26 | 14 | 6 | |
| Gender | | | | | |
| Female | 45 (45.0%) | 24 | 16 | 5 | 1.71, 0.42 |
| Male | 55 (55.0%) | 35 | 13 | 7 | |
| Dwelling | | | | | |
| Rural | 61 (61.0%) | 37 | 16 | 8 | 0.65, 0.72 |
| Urban | 39 (39.0%) | 22 | 13 | 4 | |
| Smoking status | | | | | |
| Ever | 60 (60.0%) | 36 | 17 | 7 | 0.06, 0.97 |
| Never | 40 (40.0%) | 24 | 12 | 5 | |
| Tumor location | | | | | |
| Colon | 44 (44.0%) | 21 | 17 | 6 | 4.38, 0.11 |
| Rectum | 56 (56.0%) | 38 | 12 | 6 | |
| Nodal status | | | | | |
| Involved | 57 (57.0%) | 38 | 12 | 7 | 4.22, 0.12 |
| Not Involved | 43 (43.0%) | 21 | 17 | 5 | |
| Tumor grade | | | | | |
| WD | 63 (63.0%) | 37 | 18 | 8 | 0.08, 0.96 |
| MD+PD | 37 (37.0%) | 22 | 11 | 4 | |
Arg399Gln polymorphisms are the most extensively studied SNPs (Lamerdin et al., 1995).

In this hospital-based case-control study, we investigated the relationship of DNA repair gene XRCC1 Arg194Trp polymorphism with colorectal carcinogenesis and its concomitant role in the modulation of risk of colorectal cancer in our population taking into view that our previous study on XRCC1 Arg399Gln polymorphism, had demonstrated that although there was no direct significant association between XRCC1 genotypes and CRC, but that Arg/Gln heterozygous genotype was associated with the elevated risk of CRC (OR>1.47) and Gln/Gln variant genotype was associated with an increased risk of CRC in various clinic-pathological parameters (Wang et al., 2010).

In this study we found that among the CRC cases, the frequency of the XRCC1 and Arg/Arg genotype to be 59.0 per cent (59/100), Arg/Trp to be 29.0 per cent (29/100) and Trp/Trp to be 12.0 per cent (12/100), while the frequency of XRCC1 and Arg/Arg genotype in controls was 78.0 per cent (78/100), 19.0 per cent (19/100) for Arg/Trp and 3.0 per cent (3/100) for Trp/Trp. The overall association between the XRCC1 Arg194Trp polymorphism and the CRC was found to be significant (p=0.006) (Table 4.2). We also found that variant allele (Trp) in both conditions - heterozygous (Arg/Trp) genotype and homozygous (Trp/Trp) genotype was associated with the elevated risk for CRC (OR=2.01 (95%CI=1.03-3.94)) and (OR=5.2(95%CI=1.42-19.5)) respectively.

These results are in agreement with the study of Abdel Rehman et al., (2000) on Egyptian population, who first reported the significant relationship between XRCC1 polymorphism and CRC, providing the first evidence that individuals inheriting the 194Trp variant allele of XRCC1 gene were more likely to develop CRC.

A large case control study in the United States reported that 194Trp allele, was associated with a modest increase in the risk of colon cancer with alcohol consumption (Curtin et al., 2009). Likewise Yin et al., 2012 reported individuals with the 194Arg allele showed a moderately increased risk of colorectal cancer with high alcohol consumption.

Similarly, Gao et al., (2013) reported that XRCC1 194Trp allele in interaction with the high alcohol intake played a significant role in elevating the risk of CRC (P<0.01) concluding the fact that CRC susceptibility may be altered by gene-environment interactions. Furthermore the meta-analysis by Mao et al., (2013) suggests that the XRCC1 Arg194Trp polymorphism may modify the risk for CRC, particularly in patients with colon cancer. Also XRCC1 and Arg194Trp SNP has been indicated as modifier of the effect of tobacco smoking and alcohol consumption on CRC risk, suggesting the role of gene-environment interaction in colorectal carcinogenesis.

However, our results were not consistent with many other studies like Hong et al., (2005) and Importa et al., (2008) which suggested that XRCC1 polymorphism might have multiple and subtle influences on the carcinogenesis. They have also suggested that the effects are modulated by several genetic factors and/or environmental exposures.

However, few studies reported a reduced risk of cancer associated with the XRCC1 194Trp variant form (Lamerdin et al., 1995; Duell et al., 2001; Mort et al., 2003) while as other study by Sjelkbred et al., (2006) and Muñiz-Mendoza et al., (2012) reported no association of codon 194 polymorphism with the risk of CRC, in a similar way as reported by Li et al., (2014) for hepatocellular carcinoma.

The divergence in results from different studies on XRCC1 polymorphism may be related to variation in carcinogenic exposure and ethnic origin of the studied population (Hong et al., 2005; Stern et al., 2005; Moreno et al., 2006; Berndt et al., 2007; Sliwinski et al., 2008). Since carcinogenesis is a complex process and inter related pathways of biological response to DNA damage exist involving multiple genetic mechanisms, therefore such inconsistency in results among different populations can be attributed to the fact that polymorphism might have multiple effects on cancer formation, which depend on other genetic factors or environmental exposures. The small sample size plus other confounding factors like age, gender, diet and lifestyle may attribute to such differences.

The contradictory findings among different case-control studies might be attributed to different sample size, source of controls, genotyping method and matching criteria of subjects, and so on. In addition, the potential gene-gene and gene-environment interactions may also play vital roles in the pathogenesis.

In conclusion, our results suggest an increased risk for CRC in individuals with XRCC1 Arg194Trp polymorphism suggesting BER repair pathway modulates the risk of developing colorectal cancer in Kashmiri population.

Acknowledgements

The authors wish to thank each and every CRC patient who took part in this study and cooperated during the interview and sample collection. The authors gratefully acknowledge the financial support provided by the Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Soura, Kashmir, for this work. We also thank the Department of Immunology & Molecular Medicine, SKIMS, Soura, Kashmir for providing all the technical support. We also thank the head and technical staff of the operating theatre in the Department of General Surgery, SKIMS, Soura, Kashmir who helped us with tissue procurement, and the anonymous pathologists at the Department of Pathology, SKIMS, Soura, Kashmir for the histopathological assessment of the tumour tissues.

References

Abdel-Rahman SZ, Soliman AS, Bondy ML, et al (2000). Inheritance of the 194Trp and the 399Gln variant alleles of the DNA repair gene XRCC1 are associated with increased risk of early-onset colorectal carcinoma in Egypt. Cancer Lett, 159, 79-86.

Berndt SI, Huang WY, Fallin MD, Hezlsouer KJ, Platz EA, Weissfeld JL, et al (2007). Genetic variation in base excision repair genes and the prevalence of advanced colorectal adenoma. Cancer Res, 67, 1395-1404.

Berwick M and Vineis P (2000). Markers of DNA repair and...
susceptibility in humans: an epidemiological review. J Natl Cancer Inst, 91, 874-97.

Brem R and Hall J (2005). XRCC1 is required for DNA single-strand break repair in human cells. Nucleic Acids Research, 33, 2512-20.

Chen B, Zhou Y, Yang P, Wu XT (2012). Polymorphisms of XRCC1 and gastric cancer susceptibility, a meta-analysis. Mol Biol Rep, 39, 1305-13.

Chiyomaru K, Nagano T, Nishigori C (2012). XRCC1 Arg194Trp polymorphism risk of nonmelanoma skin cancer and extramammary Paget’s disease in a Japanese population. Arch Dermatol Res, 304, 363-70.

Christmann M, Tomicic MT, Roos WP, Kaina B (2003). Mechanisms of human DNA repair, an update. Toxicology, 193, 3-34.

Curtin K, Samowitz WS, Wolff RK, et al (2009). Assessing tumor mutations to gain insight into base excision repair sequence polymorphisms and smoking in colon cancer. Cancer Epidemiol Biomarkers Prev, 18, 3384-8.

Custódio AC, Almeida LO, Pinto GR, et al (2011). Polymorphisms of the DNA repair genes XRCC1 and XRCC3 and risk of colorectal cancer and gastric cancer. Carcinogenesis, 32, 1513-30.

Duell EJ, Millikan RC, Pittman GS, et al (2001). Polymorphisms in the XRCC1 gene, alcohol consumption and colorectal cancer. Cancer Epidemiol Biomark Prev, 10, 201-10.

Du Y, Han LY, Li DD, et al (2013). Associations between XRCC1 Arg399Gln, Arg194Trp, and Arg280His polymorphisms and risk of differentiated thyroid carcinoma, a meta-analysis. Asian Pac J Cancer Prev, 14, 5483-7.

Duarte MC, Colombo J, Rossit AR, et al (2005). Polymorphisms of DNA repair genes XRCC1 and XRCC3, interaction with environmental exposure and risk of chronic gastritis and gastric cancer. World J Gastroenterol, 11, 6593-600.

Duell EJ, Millikan RC, Pfitzmann GS, et al (2001). Polymorphisms in the DNA repair gene XRCC1 and breast cancer. Cancer Epidemiol Biomark Prev, 10, 217-222.

Feng YZ, Liu YL, He XF, et al (2014) Association between the XRCC1 Arg194Trp polymorphism and risk of cancer, evidence from 201 case-control studies. Tumour Biol, 35, 10677-97.

Friedberg EC (2003). DNA damage and repair. Nature, 421, 436-40.

Gao CM, Ding JH, Li SP, et al (2013). Polymorphisms of XRCC1 gene, alcohol drinking, and risk of colorectal cancer, a case-control study in Jiangsu Province of China. Asian Pac J Cancer Prev, 14, 6613-8.

Gellad ZF, Provenzale D (2010). Colorectal cancer, national and international perspective on the burden of disease and public health impact. Gastroenterology, 138, 2177-90.

Goode EL, Ulrich CM, Potter JD (2002). Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev, 11, 1513-30.

Hoeijmakers JHH (2001). Genome maintenance mechanisms for preventing cancer. Nature, 411, 366-374.

Hong YC, Lee KH, Kim WC, Choi SK, Woo ZH, Shin SK et al. (2005). Polymorphisms of XRCC1 gene, alcohol consumption and colorectal cancer. Int J Cancer, 116, 428-432.

Imprinta G, Sgambrato A, Bianchino G, et al (2008). Polymorphisms of the DNA repair genes XRCC1 and XRCC3 and risk of lung and colorectal cancer, a case-control study in a Southern Italian population. Anticancer Res, 28, 2941-6.

Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.

Lamerdin JE, Montgomery MA, Stiilwagen SA, Scheidecker LK, Tebbs RS, Brookman KW, et al (1995). Genomic sequence comparison of the human and mouse XRCC1 DNA repair gene regions. Genomics, 25, 547-54.

Lee SG, Kim B, Choi J, Kim C, Lee I, Song K (2002). Genetic polymorphisms of XRCC1 and risk of gastric cancer. Cancer Letters, 187, 53-60.

Li J, Mu L, Wei G (2005). Relationship between polymorphisms of DNA repair gene XRCC1 and susceptibility to lung cancer. China Oncology, 15, 335-8.

Li W, Yang F, Gui Y, Bian J (2014). DNA repair gene XRCC1 Arg194Trp polymorphism and susceptibility to hepato-cellular carcinoma, A meta-analysis. Oncol Lett, 8, 1725-30.

Lindahl T, Wood RD (1999). Quality control by DNA repair. Science, 286, 1897-1905.

Liu C, Yin Q, Li L, et al (2013). XRCC1 Arg194Trp and Arg280His polymorphisms in bladder cancer susceptibility, meta-analysis. Crit Rev Eukaryot Gene Exp, 23, 339-54.

Mao D, Zhang Y, Lu H, FuX (2013). Association between X-ray repair cross-complementing group 1 Arg194Trp polymorphism and colorectal cancer risk. Tumor Biol, 34, 2529-38.

Marsin S, Vidal AE, Sossou M, et al (2003). Role of XRCC1 in the coordination and stimulation of oxidative DNA damage repair initiated by the DNA glycosylase hOGG1. J Biological Chemistry, 278, 44068-74.

Maynard S, Schurman SH, Harboe C, de Souza-Pinto NC, Bohr VA (2009). Base excision repair of oxidative DNA damage and association with cancer and aging. Carcinogenesis, 30, 2-10.

Mir MM, Dar NA, Gochhait S, et al (2005). p53 Mutation profile of squamous cell carcinomas of the esophagus in Kashmir (India), a high-incidence area. Int J Cancer, 116, 62-68.

Moreno V, Gemignani F, Landi S, et al (2006). Polymorphisms in genes of nucleotide and base excision repair, risk and prognosis of colorectal cancer. Clin Cancer Res, 12, 2101-8.

Mort R, Mo L, McEwan C, Melton DW (2003). Lack of involvement of nucleotide excision repair gene polymorphisms in colorectal cancer. Br J Cancer, 89, 333-7.

Muniz-Mendoza R, Ayala-Madrigal ML, Partida-Perez M, et al (2012). MLH1 and XRCC1 polymorphisms in Mexican patients with colorectal cancer. Genet Mol Res, 11, 2315-20.

Naccarati A, Pardini B, Hemminki K, Vodika P (2007). Sporadic colorectal cancer and individual susceptibility, a review of the association studies investigating the role of DNA repair genetic polymorphisms. Mutat Res, 635, 118-45.

Nissar S, Lone TA, Banday MZ, et al (2013). XRCC1 Arg399Gln polymorphism and risk of colorectal cancer, a case control study in Kashmiri Population. Oncol Lett, 8, 959-63.

Rasool MT, Lone MM, Wani ML, et al (2012). Cancer in Kashmir, India, Burden and pattern of disease. J Can Res Ther, 8, 243-6.

Sameer AS, Nissar S, Abdullah S, Chowdri NA, Siddiqui MA (2012). DNA repair gene S-oxyguanine DNA glycosylase Ser326Cys polymorphism and colorectal cancer risk in a Kashmiri population. DNA Cell Biol, 31, 541-6.

Sameer AS (2013a). Colorectal cancer, a researcher’s perspective of the molecular angel’s gone eccentric in the Vale of Kashmir. Tumor Biol, 34, 1301-15.

Sameer AS (2013b). Colorectal cancer, molecular mutations and polymorphisms. Front Oncol, 3, 114.

Shen MR, Jones IM, Mohrenweiser H (1998). Non conservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res, 58, 604-8.

Skelbred CF, Sæbø M, Wallin H, et al (2006). Polymorphisms of the XRCC1, XRCC3 and XPD genes and risk of colorectal adenoma and carcinoma, in a Norwegian cohort, a case control study. BMC Cancer, 16, 67.

Sliwiński T, Krupa R, Wisniewska-Jarosinska M, et al (2008).
No association between the Arg194Trp and Arg399Gln polymorphisms of the XRCCI gene and colorectal cancer risk and progression in a Polish population. *Exp Oncol*, 30, 253-254.

Stern MC, Conti DV, Siegmund KD, et al (2007). DNA repair single-nucleotide polymorphisms in colorectal cancer and their role as modifiers of the effect of cigarette smoking and alcohol in the Singapore Chinese Health Study. *Cancer Epidemiol Biomark Prev*, 16, 2363-2372.

Stern MC, Siegmund KD, Corral R, Haile RW (2005). XRCC1 and XRCC3 polymorphisms and their role as effect modifiers of unsaturated fatty acids and antioxidant intake on colorectal adenomas risk. *Cancer Epidemiol Biomarkers Prev*, 14, 609-615.

Thompson LH and West MG (2000). XRCC1 keep DNA from getting stranded. *Mutation Research*, 459, 1-18.

Vidal AE, Boiteux S, Hickson ID, Radicella JP (2001). XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein-protein interactions. *EMBO Journal*, 20, 6530-6539.

Wang J, Zhao Y, Jiang J, et al (2010). Polymorphisms in DNA repair genes XRCC1, XRCC3 and XPD, and colorectal cancer risk, a case-control study in an Indian population. *J Cancer Res Clin Oncol*, 136, 1517-1525.

Wood RD, Mitchell M, Sgouros J, Lindahl T (2001). Human DNA repair genes. *Science*, 291, 1284-1289.

Yeh C-C, Sung F-C, Tang R, Chang Chieh C, Hsieh L-L (2005). Polymorphisms of the XRCC1, XRCC3, and XPD genes, and colorectal cancer risk, a case-control study in Taiwan. *BMC Cancer*, 5, 12.

Yin G, Morita M, Ohnaka K, et al (2012). Genetic polymorphisms of XRCC1, alcohol consumption, and the risk of colorectal cancer in Japan. *J Epidemiol*, 22, 64-71.

Yu Z, Chen J, Ford BN, Brackley ME, Glickman BW (1999). Human DNA repair systems, an overview. *Environ Mol Mutagen*, 33, 3-20.

Zhang Y, Wang Y, Wu J, Li LJ (2013). XRCC1 Arg194Trp polymorphism is associated with oral cancer risk, evidence from a meta-analysis. *Tumour Biol.*, 34, 2321-2327.